ClinicalTrials.gg
RecruitingNCT07030686Updated Nov 18, 2026

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

An observational study in Survivorship, Recurrent and Recurrence, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionNeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.
Updated Oct 29, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
70,000
Ages
18 Years and older
Sex
All
01

Study summary

This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.

02

Conditions studied

  • Survivorship
  • Recurrent
  • Recurrence
  • Cancer
  • Remission

Browse trials for

Keywords

  • Survivorship
  • Exercise
  • cancer survivor
  • adult cancer survivor
  • no evidence of disease
  • 20-101
  • Memorial Sloan Kettering Cancer Center
03

In context

Neoplasms Reclassified

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 70,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.

Eligibility criteria

Inclusion Criteria:

Target trial (ideal RCT)

  • Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).
  • Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status [i.e., reporting \<10 metabolic equivalent-hours per week (MET-h/week)]. Patients completing an additional exercise survey between th and baseline are excluded.
  • No evidence of recurrent or disease in the 15 months prior to the baseline exercise assessment
  • Completion of all definitive primary therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.
  • Undergoing surveillance in the Cancer Survivorship Program at MSK

Emulation using observational data

  • Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.
  • Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).
  • Non-exercising (i.e., reporting \<5 MET-h/week) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).
  • Documented history of the following absolute to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.
  • No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.
  • Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
70,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Arm 1: Usual Care
  • Arm 2: Exercise

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    Exercise following completion of active treatment for the primary index cancer

06

What researchers measure

Primary outcomes

  1. Distant disease-free survival (DDFS)

    To estimate the association of exercise vs. usual care (control) with Distant disease-free survival (DDFS) among patients following the completion of active treatment for the primary index cancer being monitored at MSK.

    Time frame: 5 years

07

Study locations

1 of 3 sites recruiting
  • University of California, Los Angeles (Data or Specimen Analysis Only)
    Los Angeles, California 90095-1781, United States
    Not yet recruiting
    • Paul Boutros, PhD · Contact310-794-7160
  • Weill Cornell Medical College (Data or Specimen Analysis Only)
    New York, New York 10021, United States
    Not yet recruiting
    • Xiaoyue Ma · Contact646-962-8029
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8093
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Mar 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 22, 2025
StartActual
Mar 19, 2020
Primary completionEst.
Mar 19, 2027
CompletionEst.
Mar 19, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
61100→70000
Oct 29, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 29, 2026
    Enrollment 61100→70000
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030686
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Mar 19, 2020
Primary completion
Mar 19, 2027 (estimated)
Completion
Mar 19, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jessica Scott, PhD
Contact
scottj1@mskcc.org
646-888-8093
Chaya Moskowitz, PhD
Contact
moskowc1@MSKCC.ORG
646-227-3607
Jessica Scott, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion